
#10 - Matt Kaeberlein, Ph.D.: rapamycin and dogs — man’s best friends? — living longer, healthier lives and turning back the clock on aging, and age-related diseases
The Peter Attia Drive
00:00
I'm Not Betting on the Path That We End Up Taking, Right?
There's not a lot of money in rapaicin, so i don't know who's going to find those trials. So either it's going to be rapaic in derivatives that are under pattern,. like novartisis has developed, and now restore bio is further developing. Or it's going To be alternative funding sources, whether that's foundations or wealthy individuals who recognize the potential impact of this work and are willing to fund a clinical trial actually start to love.
Transcript
Play full episode